Germany · Delayed Price · Currency is EUR Rocket Pharmaceuticals Statistics
Total Valuation
FRA:9IP1 has a market cap or net worth of EUR 294.17 million. The enterprise value is 124.10 million.
| Market Cap | 294.17M |
| Enterprise Value | 124.10M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 108.22M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.70% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 2.75% |
| Owned by Institutions (%) | 66.83% |
| Float | 78.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.10 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.60 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.72 |
Financial Position
The company has a current ratio of 7.30, with a Debt / Equity ratio of 0.08.
| Current Ratio | 7.30 |
| Quick Ratio | 7.15 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | -130.71 |
Financial Efficiency
Return on equity (ROE) is -74.88% and return on invested capital (ROIC) is -44.51%.
| Return on Equity (ROE) | -74.88% |
| Return on Assets (ROA) | -40.56% |
| Return on Invested Capital (ROIC) | -44.51% |
| Return on Capital Employed (ROCE) | -73.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -686,720 |
| Employee Count | 299 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -78.89% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 3.90 |
| Relative Strength Index (RSI) | 54.49 |
| Average Volume (20 Days) | 395 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -210.67M |
| Pretax Income | -205.33M |
| Net Income | -205.33M |
| EBITDA | -201.15M |
| EBIT | -210.67M |
| Earnings Per Share (EPS) | -1.91 |
Balance Sheet
The company has 189.86 million in cash and 21.35 million in debt, giving a net cash position of 168.51 million.
| Cash & Cash Equivalents | 189.86M |
| Total Debt | 21.35M |
| Net Cash | 168.51M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 267.34M |
| Book Value Per Share | 2.47 |
| Working Capital | 167.49M |
Cash Flow
In the last 12 months, operating cash flow was -172.26 million and capital expenditures -570,189, giving a free cash flow of -172.83 million.
| Operating Cash Flow | -172.26M |
| Capital Expenditures | -570,189 |
| Free Cash Flow | -172.83M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:9IP1 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.70% |
| Shareholder Yield | -14.70% |
| Earnings Yield | -69.80% |
| FCF Yield | -58.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |